Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226610 · ClinicalTrials.gov registry record · Phase 2
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
A Phase 2 study of Pruritis, sponsored by Akron Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06226610 is a Phase 2 study of Pruritis that is actively recruiting participants, run by Akron Children's Hospital. The registered enrollment target is 46 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06226610, a Phase 2 study of Pruritis, is actively recruiting participants, sponsored by Akron Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
Study Locations (1)
Ohio
- Akron Children's Hospital - Akron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06226610
The ClinicalTrials.gov registry entry for NCT06226610 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akron Children's Hospital, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pruritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06226610 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06226610 about?
NCT06226610 is a clinical study titled "Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic". The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
What is the current status of trial NCT06226610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-11-21. Estimated completion is 2026-12-31.
What conditions does trial NCT06226610 study?
This clinical trial studies the following conditions: Pruritis.
What interventions are being tested in trial NCT06226610?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06226610?
This trial is sponsored by Akron Children's Hospital, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226610 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.